Michael J Townsend
Overview
Explore the profile of Michael J Townsend including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie M, Dai B, Hackney J, Sun T, Zhang J, Jackman J, et al.
Cell Rep Med
. 2023 Jul;
4(8):101130.
PMID: 37490914
Signal regulatory protein (SIRPα) is an immune inhibitory receptor expressed by myeloid cells to inhibit immune cell phagocytosis, migration, and activation. Despite the progress of SIRPα and CD47 antagonist antibodies...
2.
Orozco L, Owen L, Hofmann J, Stockwell A, Tao J, Haller S, et al.
Cell Genom
. 2023 Jun;
3(6):100302.
PMID: 37388919
Age-related macular degeneration (AMD) is a leading cause of blindness, affecting 200 million people worldwide. To identify genes that could be targeted for treatment, we created a molecular atlas at...
3.
Orozco L, Chen H, Cox C, Katschke Jr K, Rommel Arceo , Espiritu C, et al.
Cell Rep
. 2023 Mar;
42(3):112298.
PMID: 36952338
No abstract available.
4.
McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, et al.
J Med Chem
. 2022 Oct;
65(21):14721-14739.
PMID: 36279149
Inappropriate activation of the NLRP3 inflammasome has been implicated in multiple inflammatory and autoimmune diseases. Herein, we aimed to develop novel NLRP3 inhibitors that could minimize the risk of drug-induced...
5.
Roodenrijs N, Welsing P, van Roon J, Schoneveld J, van der Goes M, Nagy G, et al.
Rheumatology (Oxford)
. 2022 Mar;
61(9):3552-3566.
PMID: 35238332
Management of RA patients has significantly improved over the past decades. However, a substantial proportion of patients is difficult-to-treat (D2T), remaining symptomatic after failing biological and/or targeted synthetic DMARDs. Multiple...
6.
Isenberg D, Furie R, Jones N, Guibord P, Galanter J, Lee C, et al.
Arthritis Rheumatol
. 2021 May;
73(10):1835-1846.
PMID: 34042314
Objective: Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed...
7.
Tokuyama M, Gunn B, Venkataraman A, Kong Y, Kang I, Rakib T, et al.
J Exp Med
. 2021 May;
218(7).
PMID: 34019642
Neutrophil activation and the formation of neutrophil extracellular traps (NETs) are hallmarks of innate immune activation in systemic lupus erythematosus (SLE). Here we report that the expression of an endogenous...
8.
Corzo C, Varfolomeev E, Setiadi A, Francis R, Klabunde S, Senger K, et al.
Sci Signal
. 2020 Jun;
13(634).
PMID: 32487715
The dysregulation of multiple signaling pathways, including those through endosomal Toll-like receptors (TLRs), Fc gamma receptors (FcγR), and antigen receptors in B cells (BCR), promote an autoinflammatory loop in systemic...
9.
Cohen S, Tuckwell K, Katsumoto T, Zhao R, Galanter J, Lee C, et al.
Arthritis Rheumatol
. 2020 Apr;
PMID: 32270926
Objective: To evaluate fenebrutinib, an oral and highly selective non-covalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA). Methods: Patients with RA and inadequate response...
10.
Kinloch A, Cascino M, Dai J, Bermea R, Ko K, Vesselits M, et al.
Lupus
. 2020 Mar;
29(6):569-577.
PMID: 32216516
No abstract available.